TYK Medicines’ EGFR inhibitor demonstrates promising results in lung cancer patients with brain metastases. Tagrisso and asandeutertinib have shown activity in EGFR-mutated NSCLC with central nervous system metastases. In the Phase III FLAURA 1 trial, patients on Tagrisso had a median progression-free survival of 15.2 months, outperforming standard therapy with another EGFR inhibitor. Additionally, the Phase III MARIPOSA trial investigated Johnson & Johnson’s Rybrevant and Lazcluze in EGFR-mutant NSCLC, showing improved outcomes in patients with brain metastases on the combination therapy.
Read more from precisionmedicineonline.com
